US equities |
NVDA $238.57 ▲+1.97% SPCX $167.27 ▲+5.23% MU $1,062.67 ▼-1.14% TSLA $380.30 ▲+2.62% MSFT $525.62 ▲+1.56% SNDK $1,705.80 ▼-0.82% INTC $117.20 ▼-1.78% META $742.79 ▲+2.02%
FinancialContent

NovoCure Limited - Ordinary Shares (NQ:NVCR)

14.98 +0.04 (+0.27%)
Delayed Quote Updated: 2:37 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Novocure Reports First Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
NovoCure's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
News headline image
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why ↗
Via The Motley Fool
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Why NovoCure Stock Was Withering on Wednesday ↗
Via The Motley Fool
News headline image
Novocure to Report First Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
From Novocure
Via Business Wire
News headline image
NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025 ↗
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
News headline image
Why NovoCure Stock Was Winning Big This Week ↗
Via The Motley Fool
News headline image
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds ↗
The company is soon to seek regulatory approval in the U.S. and abroad. 
Via Investor's Business Daily
News headline image
NovoCure Q4 EPS Misses, Revenue Matches ↗
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
News headline image
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Novocure
Via Business Wire
News headline image
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
From Novocure
Via Business Wire
News headline image
Navigating 5 Analyst Ratings For NovoCure ↗
 
Via Benzinga
News headline image
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
News headline image
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
News headline image
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
News headline image
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates ↗
 
Via Benzinga
Topics Stocks
News headline image
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
News headline image
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >